Skip to content
10-Q

Quarterly Report

Kailera Therapeutics, Inc. KLRA

0001193125-26-239417

← back to feed
Filed
May 26, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 20, 2026 129.57M sh
Shares Diluted Q1 2026 · Mar 31, 2026 21.61K sh
Shares Diluted Q1 2026 · Mar 31, 2025 1 sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$68.31M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$18.2M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $111.83M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $160.27M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $101.78M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$432.09M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$356.46M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$235.24M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$218.77M
Current Liabilities Q1 2026 · Mar 31, 2026 $54.84M
Current Liabilities Q1 2026 · Dec 31, 2025 $46.41M
Total Liabilities Q1 2026 · Mar 31, 2026 $64.48M
Total Liabilities Q1 2026 · Dec 31, 2025 $56.39M
Current Assets Q1 2026 · Mar 31, 2026 $530.32M
Current Assets Q1 2026 · Dec 31, 2025 $557.54M
Total Assets Q1 2026 · Mar 31, 2026 $624.76M
Total Assets Q1 2026 · Dec 31, 2025 $692.29M
Eps Diluted Q1 2026 · Mar 31, 2026 −$3,650.00
Eps Diluted Q1 2026 · Mar 31, 2025 −$17,983.00
Eps Basic Q1 2026 · Mar 31, 2026 −$3,650.00
Eps Basic Q1 2026 · Mar 31, 2025 −$17,983.00
Sga Expense Q1 2026 · Mar 31, 2026 $13.79M
Sga Expense Q1 2026 · Mar 31, 2025 $10.33M
Rd Expense Q1 2026 · Mar 31, 2026 $70.87M
Rd Expense Q1 2026 · Mar 31, 2025 $10.13M
Net Income Q1 2026 · Mar 31, 2026 −$78.87M
Net Income Q1 2026 · Mar 31, 2025 −$17.98M
Operating Income Q1 2026 · Mar 31, 2026 −$84.66M
Operating Income Q1 2026 · Mar 31, 2025 −$20.46M